AMR Rapid Diagnostic Tests


Research Network: 2017-01-01 - 2017-12-31
Total sum awarded: €50 000

Antimicrobial Resistance (AMR) has become a global threat and rapid diagnostics are urgently needed to tackle this challenge. To identify barriers to the development, implementation and use of rapid diagnostics and propose a roadmap to future solutions we are launching AMR Rapid Diagnostic Tests (AMR-RDT) as a multi-sectoral, multi-stakeholder and interdisciplinary working group with global reach. It brings together over 50 key individuals and organisations from 15 countries worldwide that are active in the field of diagnostics and antimicrobial resistance. This unprecedented body of expertise and the access it brings to national and international institutions, and networks will amplify the reach and implementation of the working group’s outputs. AMR-RDT will concentrate on five overarching topics: Need & Target Product Profiles, Technologies, Development Roadmaps, Business Models, and Behavioural Change. The working group will focus on human healthcare but also recognises the importance of One Health aspects. AMR-RDT is funded as a one-year project by the UK Medical Research Council under the frame of the Joint Planning Initiative on AMR (JPIAMR) and is coordinated by Till Bachmann at the University of Edinburgh.

Read More
Read Less
  • Till Bachmann, University of Edinburgh, United Kingdom (Coordinator)
  • Carla Deakin, National Institute of Clinical and Health Excellence, United Kingdom (Observer)
  • Eiichi Tamiya, Osaka University, Japan (Observer)
  • Francis Moussy, World Health Organization (WHO), Switzerland (Observer)
  • Franck Molina, European Diagnostics Cluster Alliance, France (Observer)
  • Frank Apostel, R-Biopharm, Germany (Observer)
  • Frank Bier, Fraunhofer Institute for Cell Therapy and Immunology, Germany (Observer)
  • Gerd Luedke, Curetis GmbH, Germany (Observer)
  • Guido Werner, Robert Koch Institute, Germany (Observer)
  • Gunnar Skov Simonsen, University Hospital Tromsø, Norway (Observer)
  • Gyorgy Abel, Lahey Hospital & Medical Center and Harvard Medical School, USA (Observer)
  • Alasdair MacGowan, North Bristol NHS Trust, United Kingdom (Observer)
  • Herman Goossens, University of Antwerp, Belgium (Observer)
  • Johann Moran-Gilad, Ben-Gurion University, Israel (Observer)
  • James Fraser, Chipcare, Canada (Observer)
  • Jean-François de Lavison, Ahimsa Fund, France (Observer)
  • John Hays, Erasmus MC University Medical Center, Netherlands (Observer)
  • John Rex, F2G, USA (Observer)
  • Jordi Vila, University of Barcelona, Spain (Observer)
  • Karsten Becker, Friedrich Loeffler-Institute of Medical Microbiology, Germany (Observer)
  • Kate Templeton, NHS Lothian, United Kingdom (Observer)
  • Kirsten Miller-Duys, Hyrax Biosciences, South Africa (Observer)
  • Alex van Belkum, BioMérieux, France (Observer)
  • Konstantinos Mitsakakis, Hahn-Schickard, University of Freiburg, Germany (Observer)
  • Manica Balasegeram, Global Antibiotic R&D Partnership (GARDP), Switzerland (Observer)
  • Mark Woolhouse, University of Edinburgh, United Kingdom (Observer)
  • Neil Butler, Spectromics, United Kingdom (Observer)
  • Neil Woodford, Public Health England, United Kingdom (Observer)
  • Paul Savelkoul, Maastricht University, Netherlands (Observer)
  • Petra Gastmeier, Charité University Medicine, Germany (Observer)
  • Phil Lagace Wiens, University of Manitoba, Canada (Observer)
  • Ramanan Laxminarayan, Center for Disease Dynamics, Economics & Policy, India (Observer)
  • Rosanna Peeling, Liverpool School of Tropical Medicine, United Kingdom (Observer)
  • Aman Russom, KTH Royal Institute of Technology, Sweden (Observer)
  • Saturnino Luz, University of Edinburgh, United Kingdom (Observer)
  • Sören Schubert, Max von Pettenkofer Institute Munich, Germany (Observer)
  • Stephan Harbarth, University of Geneva, Switzerland (Observer)
  • Sue Hill, NHS England, United Kingdom (Observer)
  • Tracy Merlin, University of Adelaide, Australia (Observer)
  • Taslimarif Saiyed, Centre for Cellular and Molecular Platforms, India (Observer)
  • Thomas Wichelhaus, University of Frankfurt, Germany (Observer)
  • Tjeerd van Staa, Farr Institute Health Informatics Research, United Kingdom (Observer)
  • Valentina Di Gregori, University of Bologna, Italy (Observer)
  • Wouter van der Wijngaart, KTH Royal Institute of Technology, Sweden (Observer)
  • Andrew Shepherd, Omega Diagnostics, United Kingdom (Observer)
  • Wilfried von Eiff, HHL Leipzig Graduate School of Management, Germany (Observer)
  • Ann Van den Bruel, NIHR Diagnostic Evidence Cooperative, United Kingdom (Observer)
  • Annika Eriksson, HemoCue, Sweden (Observer)
  • Barbara Fallowfield, British In Vitro Diagnostics Association, United Kingdom (Observer)
  • Bill Rodriguez, Foundation for Innovative New Diagnostics (FIND), Switzerland (Observer)

Antimicrobial resistance (AMR) is set to devastate modern medicine if left unchecked. Rapid diagnostics are urgently needed that can quickly tell if antibiotics are needed and which ones to use. Many strategic initiatives and policy interventions around the globe promote the development and use of rapid diagnostics. Nevertheless, there is a substantial gap between the urgent need for rapid diagnostics versus how much they are actually used. To identify barriers of development and implementation of rapid diagnostic tests, the Transnational Working Group AMR Rapid Diagnostic Tests (AMR-RDT) was formed in 2017 from about 50 expert stakeholders and funded through the Joint Programming Initiative on Antimicrobial Resistance. This expert group has developed three major guidance publications in 2017/18. These documents address 1) how to find out which properties new diagnostic tests need to have to be accepted by end users, 2) which aspects must be considered for new diagnostic product development pathways and 3) which behavioural change is needed so a new diagnostic test is used and achieves its impact on tackling the threat of AMR. The Transnational Working Group AMR Rapid Diagnostic Tests had input to wider AMR diagnostic initiatives such as the UK Longitude Prize on Antibiotics and the Innovative Medicines Initiative and plans to continue contributing to the global fight against AMR in the future.